Considering Comorbidities when Choosing a Chronic Lymphocytic Leukemia Treatment

Video

John Allan, MD, explains how fitness level and comorbidities affect his treatment selections for chronic lymphocytic leukemia and whether he prefers fixed-duration or continuous-strategy approaches.

Video Player is loading.
Current Time 0:00
Duration 6:20
Loaded: 2.58%
Stream Type LIVE
Remaining Time 6:20
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Case: A 70-Year-Old Woman with Newly Diagnosed Chronic Lymphocytic Leukemia

    Initial Presentation:

    • A 70-year-old woman presented to her PCP for a routine checkup complaining of moderate, progressive fatigue and unintended weight loss over the last 4 months.
    • PMH: hypercholesterolemia (well controlled on medication; reports having a relatively healthy diet)
    • SH: Retired nurse; exercises at least 30 minutes per day most days of the week; enjoys spending time with her grandkids and traveling with her spouse; ~1-2 drinks in social settings per week
    • PE: vital signs WNL, right cervical lymphadenopathy~2.7 cm, spleen palpable 5 cm below costal margin, otherwise well-appearing
    • Laboratory findings:
      • WBC 186,000; 75% lymphocytes
      • Hb 9.4 g/dL
      • Platelets 85 X 109/L
    • Cr Cl: 61 ml/min
    • Flow cytometry; CD5+, CD19+, CD23+
    • beta2M, 3.8 mg/L
    • IGHV mutational status: unmutated; TP53 unmutated
    • ECOG PS 0
    • BM biopsy; diffuse infiltration by CLL

    Treatment:

    • Options for treatment were reviewed and discussed with the patient, her spouse, and the care team.
    • The decision was made to initiate the patient on fixed duration venetoclax + obinutuzumab.
    Related Content